First-in-class therapies designed to defeat chronic inflammation and fibrosis
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
150
NCT06736990
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
Phase: Phase 2
Role: Lead Sponsor
Start: Jun 20, 2025
Completion: Nov 30, 2027
Loading map...